Behavioral and pharmaceutical intervention to treat obesity and its comorbidities typically results in only a 5-10% weight loss. Thus, bariatric surgery is the most effective obesity treatment with some surgeries resulting in 30% sustained weight loss. Although this degree of weight loss has profound metabolic impact, these surgeries seem to have metabolic effects that are independent of weight loss. In support of this is the clinical literature showing rapid resolution of Type 2 diabetes mellitus (T2DM) that occurs before significant weight loss. To gain a complete understanding of the weight loss-independent effects of bariatric surgery, animal models have been developed. These are becoming more widely implemented and allow the use of pairfed or weight-matched sham-operated controls in order to gain mechanistic insights into the mode of action of bariatric surgery. Increases in anorectic gut hormones, such as glucagon-like peptide-1 and peptide YY, or decreases in the orexigenic hormone ghrelin have been seen and are implicated as mediators of weight loss-independent actions of bariatric surgery. Changes in nutrient processing and sensing may also have a mechanistic role that is independent of, or that regulates, gut hormone responses to these surgeries. Ultimately, the hope is that understanding the mechanisms of bariatric surgeries will aid in the development of less invasive surgeries or pharmacological therapies that are more specifically, and perhaps individually, targeted at weight loss and/or resolution of T2DM.
Introduction
Obesity is now an epidemic in all western societies. In the United States, given the popularity of high caloric-density fast foods, it is not surprising that behavior modification to combat obesity and its comorbidities has largely failed. In fact, when behavior modification is successful, it only achieves a 5-10% weight loss, and frequently over time weight is regained. With the recent rejection of two obesity drugs (Qnexa, Vivus, Mountain View, CA, USA; and Lorcaserin, Arena Pharmaceuticals, San Diego, CA, USA) by the Food and Drug Administration advisory panel owing to safety concerns, the already limited pipeline for drug development is likely to shrink even more as pharmaceutical companies shy away from therapeutics that may never be approved.
Thus, at this time, the most effective treatment of obesity is bariatric surgery. The amount of weight loss is three times greater than behavior modification or pharmaceutical therapy, and is sustained over time. With this, the cost reductions associated with treatment of obesity comorbidities are substantial. 1 It was formerly thought that these surgeries were so successful in inducing weight loss simply by restricting meal size or by inducing macronutrient malabsorption. However, a consensus is building that there are metabolic features of these surgeries that go over and above the well-known effects on weight loss alone. In fact, the term 'metabolic surgery' is increasingly used to describe bariatric surgeries. 2 In human studies, it is difficult to distinguish between the independent effects of surgery and the postsurgical caloric restriction and/or the rapid weight loss on metabolism. Although clinically this may not be an important distinction, understanding the mechanisms underlying the effectiveness of these surgeries could lead to development of more targeted treatments (surgical or pharmaceutical) that can be more widely implemented. This review discusses our current knowledge regarding weight loss-dependent and -independent effects of bariatric surgeries on glucose metabolism.
Metabolic effects of bariatric surgeries
It is clear that bariatric surgeries are more potent than behavioral modifications to induce greater and longer-lasting effects on weight loss. It is also clear that bariatric surgery leads to improvements in Type 2 diabetes mellitus (T2DM) (for a more extensive review see Rubino et al.
2
). Even modest weight loss benefits glucose control, 3 and because of the difficultly of including randomized weight-matched or calorically matched control groups in clinical investigations, the weight loss-independent effects of these surgeries are less clear. Long-term comparisons of surgical and lifestyle intervention show greater weight loss (in terms of magnitude and rate) and improvements in glucose homeostasis and/or cardiovascular risk factors with surgery. [4] [5] [6] Although these metabolic improvements correlate with weight loss, it is difficult to say whether the improvements in glucose homeostasis and cardiovascular risk factors were effects of the surgery that were independent of weight loss. One group has addressed this complication by comparing T2DM patients who underwent either Roux-en-Y gastric bypass (RYGB), a surgery involving gastric size reduction and intestinal rearrangement, such that ingested food bypasses B95% of the stomach, the entire duodenum and a short portion of the jejunum, or a diet intervention program at the time point when the weight loss was equivalent between the two interventions. 7 It took almost double the time (B55 compared with 32 days) to reach a similar degree of weight loss after diet compared with surgical intervention, but both groups saw improvements in glucose homeostasis. However, the data seem to indicate a better glucose response and clearly show an improved pattern of insulin secretion to an oral glucose load in the RYGB patients. Rapid resolution of T2DM, with patients sometimes being off their medications by the time they leave the hospital, and theoretically before significant weight loss, 8 is often cited to illustrate the metabolic effects of bariatric surgery. One study showed normalized fasting glucose and insulin levels (suggesting improved insulin sensitivity) just 3 weeks after laparoscopic RYGB in a combined group of diabetic and nondiabetic obese patients. 9 In the former study, patients had a nonsignificant decrease in body mass index (body mass index; 46.2-43.2 kg m
À2
), supporting a weight loss-independent effect. However, all 10 patients showed a decrease in body mass index of at least 2 kg m À2 with an average decrement of 6%. Although it is true that a 6% decrease in body mass index, or the decrease that could be seen with a week of caloric restriction, could have contributed to the improvements in glucose homeostasis, it seems unlikely that it would normalize glucose homeostasis. Even in the Look Action For Health in Diabetes (AHEAD) trial, 4 years of intensive lifestyle intervention, with exercise as a component, did not normalize glucose homeostasis in all T2DM patients. 3 It is also true that duration of diabetes could also influence the degree of remission making it difficult to compare across studies.
Although the ultimate goal is to provide a treatment for obesity and diabetes in humans, animal models have considerable potential to help us understand the mechanisms underlying the effectiveness of bariatric surgeries.
One of the benefits of animal models is that, by using pair-fed or weight-matched controls, we can begin to understand what components of the surgery are specifically weight loss-independent. Most of the work in the rodents parallels the clinical work with persistent reductions in both body weight and glucose homeostasis. One comprehensive study in rats with RYGB found the expected persistent weight loss and decreased food intake, despite the animals being maintained on a high-fat diet. 10 Improved glucose homeostasis was also found with reduced glucose responses to both oral and intraperitoneal glucose loads 10 and increased glucose-stimulated insulin secretion in isolated islets 11 compared with both sham and pair-fed rats. Interestingly, energy expenditure has also been shown to be increased with RYGB compared with pair-fed animals, which had the typical decrease in energy expenditure seen with caloric restriction. [10] [11] [12] This is an important weight loss-independent effect of the surgery as decreases in lean mass and energy expenditure limit weight loss with caloric restriction.
Mechanisms of metabolic surgeries
The most simplistic mechanism for bariatric surgeries would be via the anatomical rearrangement of RYGB. Thus, early on, two main hypotheses were developed that have dominated the literature. These are the foregut 13 and the hindgut 14 hypotheses. The foregut hypothesis postulates that nutrient bypass of the upper gut leads to the weightreducing and antidiabetic effects of the surgeries via exclusion of a yet undiscovered signal that promotes insulin resistance. Conversely, the hindgut hypothesis is that enhanced delivery of nutrients to the lower gut stimulates the release of anorexic and incretin hormones to a greater extent benefiting both body weight and glucose homeostasis.
To test the foregut hypothesis, Rubino et al. 16 performed a surgery whereby the stomach and pylorus remained intact, but nutrients were diverted into the distal jejunum in order to exclude the upper gut. These animals were compared with rats that just underwent a gastrojejunostomy, which creates a shortcut for ingested nutrients without bypassing either intestine. 15, 16 Bypassing the duodenum improved glucose homeostasis in Goto-Kakizaki rats, a non-obese diabetic rat model, compared with animals in which nutrients were allowed to flow naturally through the duodenum and jejunum. 16 However, it remains unknown what duodenal signal (or absence thereof) may be responsible for the observed improved glucose tolerance. On the other hand, a surgical model, performed almost exclusively in animals, called the ileal interposition (IT, also known as ileal transposition), in which a piece of the distal ileum is removed and reanastomosized within the jejunum, supports the hindgut hypothesis. This surgery has been shown to have modest effects on body weight, and improves Metabolic surgery D Sandoval glucose and insulin tolerance. [17] [18] [19] [20] Interestingly, these animals have also been found to have decreased fat mass, increased lean mass, improved glucose tolerance and improved lipid profiles compared both with sham-operated ad lib fed and pair-fed animals. 18 Changes in gut hormones are also significant with this surgery and will be discussed in more detail below. 17, 18, 20 The vertical sleeve gastrectomy (VSG) involves removing B80% of the stomach along the greater curvature. Interestingly, with no surgical manipulation of the intestine, the VSG is also very effective at causing sustained weight loss and improvements in glucose homeostasis in humans and rodents. [21] [22] [23] [24] [25] Our group has recently developed a rodent model of the VSG in which we see an early weight loss due to reduced food intake. 26 Even when food intake returns to sham levels, the VSG rats maintain this new lower body weight and body fat without losses in lean mass. In other words, the animals are defending a new lower body weight and this is maintained for several months postoperatively. Although this surgery may be thought of as restrictive, when the animals are calorically deprived for 3 weeks they are still able to overeat sufficiently to regain body weight when returned to ad lib feeding. However, the animals only eat enough to go back to their original body weight, rather than to the level of the sham animals. We find that this surgery is also not malabsorptive and does not change energy expenditure or leptin sensitivity. Although more research is needed to understand the mechanism behind this surgery, it is interesting to note that multiple clinical studies have shown that VSG causes similar changes in body mass and glucose homeostasis when compared with patients who have undergone RYGB. 23, 27 Therefore, it seems that several anatomical rearrangements of the gastrointestinal tract can individually influence body weight and glucose homeostasis regulation. It still remains to be seen whether these three different rearrangements (duodenal exclusion, IT and VSG) work to improve energy and/or glucose homeostasis through similar mechanisms.
Changes in gut hormones
Changes in gut hormones are often implicated as a mechanism for the benefits of bariatric surgeries. 17, 20 and increases GLP-1-positive cells within the interposed section. 18 Interestingly, Goto-Kakizaki rats that underwent either the duodenal-jejunal bypass or the IT surgery had similar improvements in oral glucose tolerance and increases in meal-induced GLP-1 release. 31 The effect on glucose tolerance was blocked in both groups with a GLP-1 receptor antagonist, suggesting that GLP-1 signaling was important in mediating the effects of both surgeries. These data support the idea that the increases in GLP-1 postoperatively are an important mechanism underlying improvements in glucose homeostasis seen with bariatric surgery. The literature on ghrelin responses to bariatric surgery is more complicated. Ghrelin is an orexigenic peptide released from enteroendocrine cells of the stomach. 32 Two early clinical studies provided the first evidence that 24-h profiles 33 and fasting levels 34 of ghrelin were reduced after RYGB. In rodents, Shin et al. 35 saw greater suppression of acylated ghrelin, the active form of ghrelin, in response to meal, similar to what has been seen in a T2DM rodent model that underwent the VSG procedure. 36 Similar decreases in postprandial total ghrelin were also seen between RYGB and VSG 1 week and 3 months postoperatively. 23 However, other studies have not shown any changes in fasting or mealinduced total ghrelin levels in RYGB patients, 27,37 but still showed significant decreases in patients with VSG. 27 Ghrelin is produced primarily in the stomach, where the enzyme ghrelin O-acyl transferase activates ghrelin by acylating a side chain. Ghrelin is found in the circulation in both acylated and desacylated forms; however, in most of the above studies, total ghrelin, rather than active ghrelin, was measured. Thus, the reason for the discrepancies may well be due to the complication of the ghrelin system and also due to the poor sensitivity of the techniques that are widely available to assess ghrelin. 38 Changes in gut hormones could certainly influence glucose homeostasis but may also influence appetite. With VSG in rats, we saw that at a time point when total 24-h food intake was similar between sham and VSG animals, the VSG animals voluntarily take in smaller more frequent meals so that the 24-h intake is similar to that in sham animals. 26 However, with RYGB, both rodents 35 and humans 39 reduce meal size without a complete compensatory rise in meal frequency. Although reviewed more extensively elsewhere in this publication, it is also important to mention that changes in food preferences seem to be altered by bariatric surgery in both human 40 and animal models, 41 and it is possible that these may also be regulated by changes in gut hormones.
Alternative mechanisms for gut hormone release
Both the RYGB and the IT surgeries increase nutrient delivery to the hindgut and both increase gut hormone responses and improve glucose homeostasis suggestive of an important role of the hindgut in mediating these responses. However, because the VSG causes similar changes in gut hormones and glucose homeostasis, it leads to speculation of whether these improvements are through similar mechanisms or whether they are completely different mechanisms with
Metabolic surgery D Sandoval similar end points. These surgeries may all influence neural anatomy of the gut, and RYGB and VSG could both influence gastric emptying. It is also possible that these anatomical rearrangements all influence, either through separate or similar mechanisms, nutrient processing and that, in turn, they lead to the pathophysiological changes influencing energy and glucose homeostasis. One intriguing hypothesis along these lines relates to data suggesting that intestinal gluconeogenesis (making glucose from non-glucose precursors), a metabolic pathway historically thought to be restricted to the liver and kidney, is an important mechanism with bariatric surgery. 42 Intestinal gluconeogenesis was found to be increased in mice that underwent an enterogastro anastomosis, where the distal jejunum was sutured to the stomach and the pyloric sphincter was ligated, excluding the duodenum and proximal jejunum from nutrient exposure. 42 Mice that underwent this surgery had reduced food intake and improved glucose homeostasis compared with mice that had gastric banding; these effects were blocked in glucose transporter 2 knockout mice and also in mice that had portal vein vagal denervation. The authors hypothesized that glucose produced by the intestine functions as portal vein signal to the central nervous system, leading to inhibition of food intake and improved glucose homeostasis. However, whether the intestine is gluconeogenic has been highly criticized. 43 Further research is needed to clarify this controversy. Changes in bile acids may also be a link between nutrient sensing and gut hormone changes and/or mechanisms for the benefits of bariatric surgeries. Besides serving as fat solubilizers, bile acids have also been found to activate nuclear transcription factors that regulate genes involved in cholesterol and glucose metabolism. 44 Bile acids have been found to be increased after IT in obese and T2DM animal models 17, 18 through increased proximal reabsorption and decreased excretion, 18 and have been reported to be elevated in humans after RYGB. 45 It has also been shown that bile acids can activate TGR5, a G-protein-coupled receptor, and that TGR5 activation regulates GLP-1 secretion. 46 Thus, changes in bile acids may be an important mediator of changes in GLP-1, glucose and energy homeostasis with bariatric surgery.
Conclusions
The development of bariatric surgeries for animal models will allow us to delve deeper into the mechanisms underlying the rapid and sustained metabolic benefits of bariatric surgeries. However, it seems we are only at the tip of the iceberg in terms of the potential mechanistic information we can gain from animal models. The responses of obese and Type 2 diabetic animals to bariatric surgeries seem to be qualitatively similar to clinical data, increasing the probability of their usefulness in understanding the mechanisms underlying these surgeries. The role of bile acids and intestinal nutrient sensing and how this might link to both the increases in GLP-1 secretion and improvements in both glucose and lipid handling are promising targets for our understanding of the physiology behind bariatric surgeries. Ultimately, the hope is that this information will allow researchers to go back to clinical work and develop less invasive surgeries or pharmacological therapies that are more specifically, and perhaps individually, targeted at weight loss and/or resolution of T2DM.
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